101. Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.
- Author
-
Uglietti A, Genco F, Donadel E, Rinaldi S, Bastiani E, Maserati R, and Meroni V
- Subjects
- Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active, Drug Monitoring, Female, HIV Infections blood, HIV Infections drug therapy, HIV Protease Inhibitors pharmacokinetics, Humans, Male, Nelfinavir analogs & derivatives, Nelfinavir pharmacokinetics, Sensitivity and Specificity, Enzyme-Linked Immunosorbent Assay, HIV Infections diagnosis, HIV Protease Inhibitors blood, Nelfinavir blood, Reagent Kits, Diagnostic
- Abstract
Therapeutic drug monitoring (TDM) is an important tool in the management of antiretroviral (ARV) therapy. The gold standard for measuring drugs plasma levels is High-Performance Liquid Chromatographic Assay (HPLC) however it is technically-demanding and time-consuming. We evaluated a new immunoenzymatic test (TDM-ELISA, Biostrands, Trieste, Italy) for nelfinavir and its active metabolite M8 in comparison with HPLC. A statistically significant difference in Ctrough between the two different tests was demonstrated but this difference was no longer significant when a value of 29% due to M8 aliquot was deleted. This faster TDM-ELISA may have an important role for TDM in HIV patients taking ARVs.
- Published
- 2007